Optimizing Transition of Care in Multiple Myeloma: Bridging the Gap Between Academic and Community Settings : Episode 6
Monitoring Adverse Events Following CAR T-Cell Therapy
A panel of oncologists in academic and community settings discuss patient monitoring practices following CAR T-cell infusions, with a focus on neurotoxicities.
- Dr. Usmani: What is your protocol for monitoring and grading of neurotoxicity, cytokine release syndrome (CRS), and other acute toxicities immediately following CAR-T cell infusion?
- Are there any subgroups of patients you have found to be at particularly high risk for delayed neurotoxicity requiring extended monitoring?
- What are your institutional guidelines around administering steroids, anti-seizure medications, or other treatments for severe neurotoxicity?
Related Content
Fostering Academic, Community Practice Collaboration for Bispecific Therapy in Multiple Myeloma
December 26th 2024Article
Experts in multiple myeloma spoke about optimal treatment strategies for patients who receive bispecific therapy, focusing specifically on facilitating a multifaceted approach between academic and community practices.
